Aprepitant for prevention of nausea and vomiting secondary to high-dose Cyclophosphamide administered to patients undergoing Autologous Peripheral Blood Stem Cells mobilization: A Phase II Trial

This is a phase II trial evaluating efficacy and safety of Aprepitant (AP) in combination with 5-HT3 antagonist and adjusted dose dexamethasone in patients receiving high-dose cyclophosphamide (CY) and filgrastim for stem cell mobilization. We used Simon’s optimal two-stage design constrained to few...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Abidi, Muneer H, Tageja, Nishant, Ayash, Lois, Abrams, Judith, Ratanatharathorn, Voravit, Al-Khadimi, Zaid, Lum, Lawrence, Cronin, Simon, Ventimiglia, Marie, Uberti, Joseph
Formato: Artigo
Idioma:Inglês
Publicado em: 2011
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3594089/
https://ncbi.nlm.nih.gov/pubmed/22193771
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00520-011-1341-3
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados